658
Views
6
CrossRef citations to date
0
Altmetric
Commentaries

Other age groups than children need to be considered as carriers of Streptococcal pneumoniae serotypes

Pages 2670-2674 | Received 23 May 2016, Accepted 29 May 2016, Published online: 26 Jul 2016

References

  • Murray J, Agócs M, Serhan F, Singh S, Deloria-Knoll M, O'Brien K, Mwenda JM, Mihigo R, Oliveira L, Teleb N, et al. Global invasive bacterial vaccine-preventable diseases surveillance–2008–2014. MMWR Morb Mortal Wkly Rep 2014; 63:1159-62; PMID:25503919
  • O'Brien KL. PCV13 impact evaluations: the obvious and the unpredicted. Pediatr Infect Dis J 2013; 32:264-5; PMID:23558322; http://dx.doi.org/10.1097/INF.0b013e3182787f89
  • Feavers I, Knezevic I, Powell M, Griffiths E, WHO Consultation on Serological Criteria for Evaluation and Licensing of New Pneumococcal Vaccines. Challenges in the evaluation and licensing of new pneumococcal vaccines, 7–8 July 2008, Ottawa, Canada. Vaccine 2009; 27:3681-8; PMID:19442421; http://dx.doi.org/10.1016/j.vaccine.2009.03.087
  • Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MP, Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis 2015; 15:535-43; PMID:25801458; http://dx.doi.org/10.1016/S1473-3099(15)70044-7
  • Hausdorff WP, Hoet B, Adegbola RA. Predicting the impact of new pneumococcal conjugate vaccines: serotype composition is not enough. Expert Rev Vaccines 2014; 30:1-16.
  • Rodrigo C, Bewick T, Sheppard C, Greenwood S, Macgregor V, Trotter C, Slack M, George R, Lim WS. Pneumococcal serotypes in adult non-invasive and invasive pneumonia in relation to child contact and child vaccination status. Thorax 2014; 69:168-73; PMID:24048505; http://dx.doi.org/10.1136/thoraxjnl-2013-203987
  • Harboe ZB, Dalby T, Weinberger DM, Benfield T, Mølbak K, Slotved HC, Suppli CH, Konradsen HB, Valentiner-Branth P. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis 2014; 59:1066-73; PMID:25034421; http://dx.doi.org/10.1093/cid/ciu524
  • Moffitt K, Malley R. Rationale and prospects for novel pneumococcal vaccines. Hum Vaccin Immunother 2016; 12:383-92; PMID:26535755; http://dx.doi.org/10.1080/21645515.2015.1087625
  • McFetridge R, Meulen AS, Folkerth SD, Hoekstra JA, Dallas M, Hoover PA, Marchese RD, Zacholski DM, Watson WJ, Stek JE, et al. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults. Vaccine 2015; 33:2793-9; PMID:25913828; http://dx.doi.org/10.1016/j.vaccine.2015.04.025
  • Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372:1114-25; PMID:25785969; http://dx.doi.org/10.1056/NEJMoa1408544
  • Theidel U, Kuhlmann A, Braem A. Pneumococcal vaccination rates in adults in Germany: an analysis of statutory health insurance data on more than 850,000 individuals. Dtsch Arztebl Int 2013; 110:743-50; PMID:24280430
  • Slotved HC, Dalby T, Hoffmann S. The effect of pneumococcal conjugate vaccines on the incidence of invasive pneumococcal disease caused by ten non-vaccine serotypes in Denmark. Vaccine 2016; 34:769-74; PMID:26772630; http://dx.doi.org/10.1016/j.vaccine.2015.12.056
  • Steens A, Vestrheim DF, Aaberge IS, Wiklund BS, Storsaeter J, Riise Bergsaker MA, Rønning K, Furuseth E. A review of the evidence to inform pneumococcal vaccine recommendations for risk groups aged 2 years and older. Epidemiol Infect 2014; 142:2471-82; PMID:24932959; http://dx.doi.org/10.1017/S0950268814001514
  • Alicino C, Barberis I, Orsi A, Durando P. Pneumococcal vaccination strategies in adult population: perspectives with the pneumococcal 13 – valent polysaccharide conjugate vaccine. Minerva Med 2014; 105:89-97. Review; PMID:24572454
  • Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine 2013; 31:6232-8; PMID:24176490; http://dx.doi.org/10.1016/j.vaccine.2013.10.032
  • Ladhani SN, Andrews NJ, Waight P, Borrow R, Slack MP, Miller E. Impact of the 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in infants younger than 90 days in England and wales. Clin Infect Dis 2013; 56:633-640; PMID:23175560; http://dx.doi.org/10.1093/cid/cis934
  • Azzari C, Cortimiglia M, Nieddu F, Moriondo M, Indolfi G, Mattei R, Zuliani M, Adriani B, Degl'Innocenti R, Consales G, et al. Pneumococcal serotype distribution in adults with invasive disease and in carrier children in Italy: Should we expect herd protection of adults through infants' vaccination? Hum Vaccin Immunother 2016; 12:344-50; PMID:26647277; http://dx.doi.org/10.1080/21645515.2015.1102811
  • Steens A, Caugant DA, Aaberge IS, Vestrheim DF. Decreased carriage and genetic shifts in the Streptococcus pneumoniae population after changing the seven-valent to the thirteen-valent pneumococcal vaccine in Norway. Pediatr Infect Dis J 2015; 34:875-83; PMID:26020410; http://dx.doi.org/10.1097/INF.0000000000000751
  • van Hoek AJ, Sheppard CL, Andrews NJ, Waight PA, Slack MP, Harrison TG, Ladhani SN, Miller E. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England. Vaccine 2014 23(32):4349-55; PMID:24657717; http://dx.doi.org/10.1016/j.vaccine.2014.03.017
  • Dagan R, Patterson S, Juergens C, Greenberg D, Givon-Lavi N, Porat N, Gurtman A, Gruber WC, Scott DA. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clin Infect Dis 2013; 57:952-62; PMID:23804191; http://dx.doi.org/10.1093/cid/cit428
  • Lee GM, Kleinman K, Pelton SI, Hanage W, Huang SS, Lakoma M, Dutta-Linn M, Croucher NJ, Stevenson A, Finkelstein JA. Impact of 13-Valent Pneumococcal Conjugate Vaccination on Streptococcus pneumoniae Carriage in Young Children in Massachusetts. J Pediatric Infect Dis Soc 2014; 3:23-32; PMID:24567842; http://dx.doi.org/10.1093/jpids/pit057
  • Gounder PP, Bruce MG, Bruden DJ, Singleton RJ, Rudolph K, Hurlburt DA, Hennessy TW, Wenger J. Effect of the 13-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae-Alaska, 2008–2012. J Infect Dis 2014; 209:1251-8; PMID:24273178; http://dx.doi.org/10.1093/infdis/jit642
  • Ricketson LJ, Wood ML, Vanderkooi OG, MacDonald JC, Martin IE, Demczuk WH, Kellner JD, Calgary Streptococcus pneumoniae Epidemiology Research (CASPER) investigators. Trends in asymptomatic nasopharyngeal colonization with Streptococcus pneumoniae after introduction of the 13-valent pneumococcal conjugate vaccine in Calgary, Canada. Pediatr Infect Dis J 2014; 33:724-30; PMID:NOT_FOUND; http://dx.doi.org/10.1097/INF.0000000000000267
  • Fleming-Dutra KE, Conklin L, Loo JD, Knoll MD, Park DE, Kirk J, Goldblatt D, Whitney CG, O'Brien KL. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type nasopharyngeal carriage. Pediatr Infect Dis J 2014; 33(Suppl 2):S152-60; PMID:24336057; http://dx.doi.org/10.1097/INF.0000000000000083
  • Moraga-Llop F, Garcia-Garcia JJ, Díaz-Conradi A, Ciruela P, Martínez-Osorio J, González-Peris S, Hernández S, de Sevilla MF, Uriona S, Izquierdo C, et al. Vaccine Failures in Patients Properly Vaccinated with 13-Valent Pneumococcal Conjugate Vaccine in Catalonia, a Region with Low Vaccination Coverage. Pediatr Infect Dis J 2016; 35:460-3; PMID:26658626; http://dx.doi.org/10.1097/INF.0000000000001041
  • Moinho R, Brett A, Ferreira G, Lemos S. Pneumococcal vaccine failure: can it be a primary immunodeficiency? BMJ Case Rep 2014; 2014; PMID:AMBIGUOUS
  • Harboe ZB, Valentiner-Branth P, Ingels H, Rasmussen JN, Andersen PH, Bjerre CC, Goldblatt D, Ashton L, Haston M, Konradsen HB, et al. Danish Pneumococcal Surveillance Collaborating Group. Pediatric invasive pneumococcal disease caused by vaccine serotypes following the introduction of conjugate vaccination in Denmark. PLoS One 2013; 8:e51460; PMID:23365635; http://dx.doi.org/10.1371/journal.pone.0051460
  • Borrow R, Heath PT, Siegrist CA. Use of pneumococcal polysaccharide vaccine in children: what is the evidence? Curr Opin Infect Dis 2012; 25:292-303. Review; PMID:22517603; http://dx.doi.org/10.1097/QCO.0b013e3283531b0f
  • Musher DM, Rodriguez-Barradas MB. Why the recent ACIP recommendations regarding conjugate pneumococcal vaccine in adults may be irrelevant. Hum Vaccin Immunother 2016; 12 :331-5; PMID:26606172; http://dx.doi.org/10.1080/21645515.2015.1098794
  • Steens A, Vestrheim DF, de Blasio BF. Pneumococcal vaccination in older adults in the era of childhood vaccination: Public health insights from a Norwegian statistical prediction study. Epidemics 2015; 11:24-31; PMID:25979279; http://dx.doi.org/10.1016/j.epidem.2015.01.001
  • Wyllie AL, Wijmenga-Monsuur AJ, van Houten MA, Bosch AA, Groot JA, van Engelsdorp Gastelaars J, Bruin JP, Bogaert D, Rots NY, et al. Molecular surveillance of nasopharyngeal carriage of Streptococcus pneumoniae in children vaccinated with conjugated polysaccharide pneumococcal vaccines. Sci Rep 2016; 6:23809; PMID:27046258; http://dx.doi.org/10.1038/srep23809
  • Esposito S, Mari D, Bergamaschini L, Orenti A, Terranova L, Ruggiero L, Ierardi V, Gambino M, Croce FD, Principi N. Pneumococcal colonization in older adults. Immun Ageing 2016; 13:2; PMID:26759599; http://dx.doi.org/10.1186/s12979-016-0057-0
  • Bruce MG, Singleton R, Bulkow L, Rudolph K, Zulz T, Gounder P, Hurlburt D, Bruden D, Hennessy T. Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska. Vaccine 2015; 33:4813-9; PMID:26247901; http://dx.doi.org/10.1016/j.vaccine.2015.07.080
  • Bosch AA, van Houten MA, Bruin JP, Wijmenga-Monsuur AJ, Trzciński K, Bogaert D, Rots NY, Sanders EA. Nasopharyngeal carriage of Streptococcus pneumoniae and other bacteria in the 7th year after implementation of the pneumococcal conjugate vaccine in the Netherlands. Vaccine 2016; 34:531-9; PMID:26667610; http://dx.doi.org/10.1016/j.vaccine.2015.11.060
  • Knol MJ, Wagenvoort GH, Sanders EA, Elberse K, Vlaminckx BJ, de Melker HE, van der Ende A. Invasive pneumococcal disease 3 years after introduction of 10-valent pneumococcal conjugate vaccine, the Netherlands. Emerg Infect Dis 2015; 21:2040-4. Erratum in: Emerg Infect Dis. 2016 Jan;22(1):161; PMID:26488415; http://dx.doi.org/10.3201/eid2111.140780
  • van der Linden M, Falkenhorst G, Perniciaro S, Imöhl M. Effects of infant pneumococcal conjugate vaccination on serotype distribution in invasive pneumococcal disease among children and adults in Germany. PLoS One 2015; 10:e0131494; PMID:26132078; http://dx.doi.org/10.1371/journal.pone.0131494

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.